Frommer, Lawrence & Haug Partner Ed Haug Fails to Fill "Communication Vacuum" Created by "The Patent '813 Story, Part II, Version 2," Further Accelerating its Path Toward "Final Resolution"

Public-at-large invited to Share Opinions, Comments and Special Information with The New York Times, Wall Street Journal and Law360 As Story's Cast of law firms Cantor Colburn and Baker Hostetler, and global pharmaceutical company Shire, silently look on

Jan 18, 2016, 20:13 ET from Lucerne Biosciences, LLC

WILMINGTON, Del., Jan. 18, 2016 /PRNewswire/ -- Lucerne Biosciences, LLC, in its recently announced role to provide logistical communications support for a unique "first of its kind self-referential narrative" called "The Patent '813 Story, Part II, Version 2," announced today that the story is further accelerating to its "final resolution."   The development takes place as Frommer, Lawrence & Haug partner Ed Haug failed to fill a "communication vacuum" explained to him earlier in the day in an email communication.  This press release that you are now reading, issued by the company, is the result of Mr. Haug's decision.  A follow-up communication was made to Mr. Haug this evening at 7:15 pm EST cc'ing the rest of the "main cast" and four journalists/reporters informing them of what was taking place as the story accelerated to its "final resolution," including planned deployment of this press release (see pp. 822-828).   The "main cast" of "The Patent '813 Story, Part II, Version 2" includes Dr. Flemming Ornskov, CEO of Shire Plc; James Harrington and David Banchik, Intellectual Property Attorneys at Shire LLC and Shire Development LLC respectively; Tatjana May, formerly of Shire but still included in the cast; Ed Haug and Sandra Kuzmich, attorneys with Frommer, Lawrence & Haug LLP; Joe Lucci and David Farisiou, attorneys with Baker Hostetler LLP; Anne Maxwell and Derek Denhart, attorneys with Cantor Colburn LLP; and Louis Sanfilippo, CEO of LCS Group, LLC and Manager of Lucerne Biosciences, LLC.  Journalists Steve Lohr of The New York Times and Ed Silverman of the Wall Street Journal, as well as Kevin Penton and Vin Gurrieri of Law360, are serving as witnesses to the communication systems platform.

Lucerne Biosciences' 7:15 PM EST communication to Mr. Haug and others this evening stated, "….  the press release below, [is] planned to go out at 8:13 pm EST tonight. There is also information below, following the signature line but before the press release draft, that is being provided to you as a matter of the public record to advance the story's 'final resolution' in the public interest.  In this light, if the NY Times, Wall Street Journal and Law360 would rather take a pass on 'The Patent '813 Story, Part II, Version 2,' the public-at-large is invited to continue it as the company and its collaborators prepare to effectively turn it over to itself beginning as early as this Wednesday, January 20, 2016.  To expedite and support the expectant and imminent transition, the public is encouraged to contact Mr. Lohr at lohr@nytimes.com, Mr. Silverman at ed.silverman@wsj.com, Mr. Gurrieri at vin.gurrieri@law360.com and Mr. Penton at kevin.penton@law360.com.  Opinions, comments and/or even special information not in the online public domain is encouraged as the company considers these four individuals across three well-established news venues to be sufficiently knowledgeable of the story's nuances to treat it fairly and in the public interest.   The public-at-large is also invited to contact any of the cast too, the emails of which are readily available from "The Patent '813 Story, Part II, Version 2," though perhaps most conveniently found in the email sent to its cast on behalf of Lucerne Biosciences, LLC today on January 18, 2016.   The date happens to be the one-year anniversary of my wife's death.  In this respect, the soon-expected press release at 8:13 pm EST is to honor her memory and spirit.  She worked as an attorney in a big NYC law firm, Clifford Chance, and anyone who knew her would appreciate that this is exactly where she would want to see the story at the one-year anniversary of her passing, especially in view of her sharp humor, directedness and even irreverence of the legal profession of which she was a part," stated Lucerne Biosciences' Manager Louis Sanfilippo.

Additional Information/Related References

The Patent '813 Story, Part II, Version 2 (updated January 18, 2016 at 7:17 PM EST) at: https://app.box.com/s/ox7k0tn1n19kxl5anz6zd35r332w00zs

Self-Referential Narrative "The Patent '813 Story, Part II, Version 2" Features "Communications Protocol Update" From Lucerne Biosciences To Shire and the Law Firms of Frommer, Lawrence & Haug, Baker Hostetler and Cantor Colburn -- Evidence of "Third Party Communication Interference" Also Communicated in Group Update -- Journalists from The New York Times, Wall Street Journal and Law360 included in Group Update" (January 17, 2016) at: http://www.prnewswire.com/news-releases/self-referential-narrative-the-patent-813-story-part-ii-version-2-features-communications-protocol-update-from-lucerne-biosciences-to-shire-and-the-law-firms-of-frommer-lawrence--haug-baker-hostetler-and-cantor-colburn-300205512.html or in PDF at: https://app.box.com/s/e60kvzlp3uzrnuh03xp1vqjqhgmxxzv0

First of its Kind Self-Referential Narrative "The Patent '813 Story, Part II, Version 2" Calls on The New York Times and Wall Street Journal to Investigate Law360 for its Role in Reporting on the Story - The Public-at-Large Also Invited to Join the Investigation (January 16, 2016) at: http://www.prnewswire.com/news-releases/first-of-its-kind-self-referential-narrative-the-patent-813-story-part-ii-version-2-calls-on-the-new-york-times-and-wall-street-journal-to-investigate-law360-for-its-role-in-reporting-on-the-story-300205470.html or in PDF at: https://app.box.com/s/swdwgasu3ygiyy23nr24gmd40jfkh30r

Lucerne Biosciences Completes Sourcing Investigation into Shire's IPR that Led to the Invalidation of the '813 Patent; Begins Accelerated Multi-Party Public Expansion Phase of its Counter-Intelligence Technology  (January 15, 2016) at: http://www.prnewswire.com/news-releases/lucerne-biosciences-completes-sourcing-investigation-into-shires-ipr-that-led-to-the-invalidation-of-the-813-patent-300205005.html  or in PDF at: https://app.box.com/s/p45yq0h0gun3scx9b8f10uxcoh7vg5q4

LCS Group Accelerates Commercialization Plan of its Exclusively Licensed '813 Patent to Treat Binge Eating Disorder with Lisdexamfetamine Dimesylate Using '813 Patent Owner's "Deception Detection Technology," Now Freely Available Online to the Global Public-at-large (January 15, 2016) at: http://www.prnewswire.com/news-releases/lcs-group-accelerates-commercialization-plan-of-its-exclusively-licensed-813-patent-to-treat-binge-eating-disorder-with-lisdexamfetamine-dimesylate-using-813-patent-owners-deception-detection-technology-now-freely-available--300205009.html   or in PDF at: https://app.box.com/s/rhdcafckys0u6tffd7vhnkj30g8k7in3

LCS Group Accelerates Commercialization of its Exclusively Licensed '813 Patent to Treat Binge Eating Disorder with Lisdexamfetamine Dimesylate Using the '813 Patent Owner's "Deception Detection Technology," Now Freely Available Online to the Global Public-at-large (January 13, 2016) at: http://www.prnewswire.com/news-releases/lcs-group-accelerates-commercialization-plan-of-its-exclusively-licensed-813-patent-to-treat-binge-eating-disorder-with-lisdexamfetamine-dimesylate-using-813-patent-owners-deception-detection-technology-now-freely-available--300204246.html or in PDF at: https://app.box.com/s/t5urotwwyasr964hcvw9afb6xi2lezuv

Lucerne Biosciences Completes Sourcing Investigation into Shire's IPR that Led to the Invalidation of the '813 Patent; Begins Accelerated Multi-Party Public Expansion Phase of its Counter-Intelligence Technology (January 11, 2016) at: http://www.prnewswire.com/news-releases/lucerne-biosciences-completes-sourcing-investigation-into-shires-ipr-that-led-to-the-invalidation-of-the-813-patent-begins-accelerated-multi-party-public-expansion-phase-of-its-counter-intelligence-technology-300202785.html or in PDF at: https://app.box.com/s/wlspsobqpnubruhegqvhfjjrxvfvd6n0

PTAB Invalidates Lucerne Biosciences' '813 Patent for the Treatment of Binge Eating Disorder with Lisdexamfetamine Dimesylate (June 13, 2015) at: http://www.prnewswire.com/news-releases/ptab-invalidates-lucerne-biosciences-813-patent-for-the-treatment-of-binge-eating-disorder-with-lisdexamfetamine-dimesylate-300098752.html or in PDF at: https://app.box.com/s/mtbj1r0kbgzx0b2l7umz1i1booloq6ke

LCS Group Announces Exclusive License from Lucerne Biosciences to Commercialize '813 Patent and '249 Application through Shire's Marketing of Lisdexamfetamine Dimesylate for Binge Eating Disorder (May 13, 2015) at: http://www.prnewswire.com/news-releases/lcs-group-announces-exclusive-license-from-lucerne-biosciences-to-commercialize-813-patent-and-249-application-through-shires-marketing-of-lisdexamfetamine-dimesylate-for-binge-eating-disorder-300083124.html or in PDF at: https://app.box.com/s/08l7mo81abdiogkm2114n6h25pnyc5gg

Lucerne Biosciences Announces Publication of Claimed Methods for Treating Binge Eating Disorder with Lisdexamfetamine Dimesylate (March 6, 2015) at: http://www.prnewswire.com/news-releases/lucerne-biosciences-announces-publication-of-claimed-methods-for-treating-binge-eating-disorder-with-lisdexamfetamine-dimesylate-300046271.html or in PDF at: https://app.box.com/s/ielhzv70bgqoi8xwa41rwi7k459vqzia

LCS Therapeutics and Lucerne Biosciences to Commercialize '813 Patent for Lisdexamfetamine Dimesylate in the Treatment of Binge Eating Disorder (December 26, 2014) at: http://www.prnewswire.com/news-releases/lcs-therapeutics-and-lucerne-biosciences-to-commercialize-813-patent-for-lisdexamfetamine-dimesylate-in-the-treatment-of-binge-eating-disorder-300013986.html or in PDF at: https://app.box.com/s/oxpqqzbt83kri117lpl0p2zmoh68uskf

Media Contact:

Louis Sanfilippo, MD
203-521-1143

Communications can be made to lucernebio@lucernebio.com

SOURCE Lucerne Biosciences, LLC